✦ LIBER ✦

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Scribed by Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PD-150 Gefitinib (Iressa)-sensitive muta

✍ Mu, X.; Li, L.; Zhang, X.; Wang, M.; Feng, R.; Cui, Q.; Zhou, H.; Guo, B. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Predictive and Prognostic Impact of Epid

✍ Han, S.-W. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 132 KB

PD-151 Mutations in the epidermal growth

✍ Nederlof, P.; Boerrigter, L.; van 't Veer, L.; Baas, P.; van Zandwijk, N. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Epidermal growth factor receptor (EGFR)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

O-195 Activating mutations (muts) in the

✍ Taron, M.; Santarpia, C.; Ichinose, Y.; Mok, T.; Massuti, B.; Queralt, C.; Sanch 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 156 KB